Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 248-983-7 | CAS number: 28348-53-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
-Acute oral toxicity:. The acute oral LD50 in male/female rats is > 7000 mg/kg bw for Sodium cumenesulphonate No significant gross abnormalities were seen at autopsy.
This show that Sodium cumenesulphonate is practically nontoxic for acute oral toxicity.
-Acute Dermal Toxicity:
The acute lethal dermal dose was found to be greater than 2000 mg/kg.
This show that Sodium cumenesulphonate is practically nontoxic for acute dermal toxicity.
- Inhalatory toxicity:
The inhalatory LC50, 4h value of sodium cumenesulphonate in Albino Wistar rats was established to exceed 770 mg/L.
This show that Sodium cumenesulphonate is practically nontoxic for acute inhalation toxicity.
It is concluded that the substance sodium cumenesulphonate does not meet the criteria to be classified for human health hazards for acute oral, inhalation and dermal effects.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
- Specific details on test material used for the study:
- CAS Number: 28348-53-0
Identity: Cumene sulfonic acid, sodium salt
Purity: 96.0%
Remarks: Substance tested is a granular solid - Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Winkelmann, Borchen, Germany
- Age at study initiation: not mentioned
- Weight at study initiation: 141 g (males); 117 g (females), mean weights
- Fasting period before study: 16 hours
- Housing: 1 - 5 animals in Makrolon cages, type III
- Diet (e.g. ad libitum): R10 Complete feed for rats ad libitum, supplied by Ssniff Spezialfutter GmbH, Soest, Germany
- Water (e.g. ad libitum): Drinking water ad libitum
- Acclimation period: 4 - 8 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 ± 1
- Humidity (%): 60 ± 5
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- feeding ad libitum (food was withheld 16 hours prior to dosing).
- Doses:
- Single oral administration of 7000 mg/kg bw (vehicle water); no controls;
feeding ad libitum (food was withheld 16 hours prior to dosing). - No. of animals per sex per dose:
- 5/sex/dose group
- Control animals:
- no
- Details on study design:
- Observations:
• Mortality/clinical signs continuously for 6 hours on day 1 and daily until day 14.
• Body weights on day 1, 7 and 14.
• Necropsy on day 14 (3/sex/dose group). - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 7 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- male: 0/5
female 2/5 - Clinical signs:
- One hour after application piloerection, slight ataxia, lateral position and increased water intake was noted. After 24 hours the surviving animals were free of symptoms.
- Body weight:
- No effects.
- Gross pathology:
- Post mortem reddening of the gastric mucosa was observed, the surviving animals showed no pathological changes in organs at necropsy.
- Interpretation of results:
- other: practically nontoxic
- Conclusions:
- The acute oral LD50 in male/female rats is > 7000 mg/kg bw. No significant gross abnormalities were seen at autopsy.
Reference
Value: Oral LD50 >7000 mg/kg bw
Dose [mg/kg bw] effect |
|
7000 |
DR |
|||
Sex |
Day |
M |
F |
M |
F |
|
Mortality |
1-14 |
0/5 |
2/5 |
|
|
|
Clinical signs(A) |
1-14 |
+ |
+ |
|
|
|
Body weight |
1-14 |
No treatment related effects |
|
|
||
Necropsy(B) |
14 |
|
+ |
|
|
|
(A)Clinical observations included increased piloerection, ataxia, lateral recumbency and
increased water intake (lasting 24 hours after dosing).
(B)In the animals that died redness of the stomach mucosa was observed.
DR is dose related. (delete this column and line; it’s not dose related since there was only
one dose.)
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 7 000 mg/kg bw
- Quality of whole database:
- Sufficient to meet requirements
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- according to guideline
- Guideline:
- other: CPSC CFR1500.40 of the Federal Hazardous Substances Act
- GLP compliance:
- not specified
- Test type:
- acute toxic class method
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 8-week old
- Housing: stainless steel cylinders with conical nose pieces.
- Acclimation period: approximately one week
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 25 to 26
- Humidity (%): 40 to 70
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- whole body
- Vehicle:
- air
- Details on inhalation exposure:
- The collected amount of the test substance in the air sample was measured gravimetrically. Sample volumes were measured by means of a dry gas meter (type G 1.6, Actaris Meterfabriek B.V., Dordrecht, The Netherlands).
- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observations for viability were recorded once before exposure on the day of exposure (test day 1), three times during exposure, immediately and 1 h after exposure on test day 1 and twice daily during the observation period. Each animal was examined three times during exposure, immediately and 1 h after exposure on test day 1 and once daily during the observation period. Observations were detailed and carefully recorded using explicitly defined scales as appropriate. Only grossly abnormal signs were detectable during exposure as the animals were restrained in the exposure tubes. The body weight of each animal was recorded on test days 1 (before exposure), 2, 4, 8 and 15 (before necropsy).
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, - Analytical verification of test atmosphere concentrations:
- no
- Duration of exposure:
- ca. 4 h
- Concentrations:
- 770 mg/L
- No. of animals per sex per dose:
- Number of Animals per Dose: 10 (5 males, 5 females)
- Control animals:
- yes
- Details on study design:
- The collected amount of the test substance in the air sample was measured gravimetrically. Sample volumes were measured by means of a dry gas meter (type G 1.6, Actaris Meterfabriek B.V., Dordrecht, The Netherlands).
- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observations for viability were recorded once before exposure on the day of exposure (test day 1), three times during exposure, immediately and 1 h after exposure on test day 1 and twice daily during the observation period. Each animal was examined three times during exposure, immediately and 1 h after exposure on test day 1 and once daily during the observation period. Observations were detailed and carefully recorded using explicitly defined scales as appropriate. Only grossly abnormal signs were detectable during exposure as the animals were restrained in the exposure tubes. The body weight of each animal was recorded on test days 1 (before exposure), 2, 4, 8 and 15 (before necropsy).
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, - Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 770 mg/L air
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Remarks on result:
- other: powdered test substance
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 770 000 mg/m³ air
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Mortality:
- No mortality occurred.
- Clinical signs:
- other: No clinical signs were noted during exposure. After exposure, ptosis and/or piloerection were noted in two males and one female on Day 1 only.
- Body weight:
- Overall body weight gain in males and females was within the range expected for rats of this strain and age used in this type of study.
- Gross pathology:
- none
- Interpretation of results:
- other: not classified
- Remarks:
- practically nontoxic
- Conclusions:
- The inhalatory LC50, 4h value of sodium cumenesulphonate in Albino Wistar rats was established to exceed 770 mg/L.
- Executive summary:
The inhalatory LC50, 4h value of sodium cumenesulphonate in Albino Wistar rats was established to exceed 770 mg/L.
Reference
To convert mg/l into mg/m³
1m³=1000L
1 mg/m³=mg/l x 1000, 770mg/l x1000=770 000 mg/m³
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 770 000 mg/m³
- Quality of whole database:
- Sufficient to meet requirements
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- GLP compliance:
- not specified
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rabbit
- Strain:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Not available
- Age at study initiation: Not available
- Weight at study initiation: 2703 grams (Abraded skin), 2730 grams (Intact skin)
- Fasting period before study: Not available
- Housing: Not available
- Diet (e.g. ad libitum): Not available
- Water (e.g. ad libitum): Not available
- Acclimation period: Not available - Type of coverage:
- occlusive
- Vehicle:
- not specified
- Details on dermal exposure:
- TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2 ml/kg bw
- Concentration (if solution): Not available
- Constant volume or concentration used: yes
- For solids, paste formed: Not available
VEHICLE
- Amount(s) applied (volume or weight with unit): Not available
- Concentration (if solution): Not available
- Lot/batch no. (if required): Not available
- Purity: Not available - Duration of exposure:
- 24 hr
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 3 male and 3 female
- Control animals:
- not specified
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Not available
- Necropsy of survivors performed: Not available
- Other examinations performed: Clinical signs, body weight - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- act. ingr.
- Mortality:
- No mortality was observed exposure to 2000 mg/kg of the undiluted test material.
- Clinical signs:
- Sodium Cumene Suphonate elicited moderate primary irritation on the test sites.
- Body weight:
- Normal body weight gain.
- Gross pathology:
- All terminal autopsy findings were normal.
- Interpretation of results:
- other: not classified
- Remarks:
- Criteria used for interpretation of results: EU
- Conclusions:
- The acute lethal dermal dose was found to be greater than 2000 mg/kg.This test substance is practically non toxic.
- Executive summary:
The clipped skin on the backs of three male and three female rats were exposed to the test material under an occlusive dressing for 24 hours and observed for another 14 days. Results indicate slight erythema and slight oedema but no acute mortality. The dermal LD50 is > 2000 mg/kg.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- Sufficient to meet requirements
Additional information
Justification for classification or non-classification
Based on the hazard assessment of Sodium cumenesulphonate, in section 2.1 and 2.2. in IUCLID 6., available data for the substance and following the “Guidance on Information Requirement and Chemical Safety Assessment R.8. Characterisation of dose [concentration]- response for human health”, according to the EU’s list of dangerous substances (OJEC No L200/130.7.99)and according to the criteria described in Directive 67/548 and in the CLP Regulation:
Directive 67/548 |
Very Toxic (T+) R28: Very toxic if swallowed R27: Very toxic in contact with skin R26: Very toxic by inhalation R39/26 R39/27 R39/28: Dangerous of very serious irreversible effects Toxic (T): R25: Toxic if swallowed R24: Toxic in contact with skin R23: Toxic by inhalation R39/23 R39/24 R39/25: Danger of very serious irreversible effects Harmful (Xn): R22: Harmful if swallowed R21: Harmful in contact with skin R20: Harmful by inhalation R65: Harmful may cause lung damage if swallowed R21/22 Harmful; Harmful in contact with skin and if swallowed. R68/20 R68/21 R68/22: Possible risk of irreversible effects Other toxicological properties R67: Vapours may cause drowsiness and dizziness |
CLP |
H300 Acute Tox. 2 Fatal if swallowed H310 Acute Tox. 1 Fatal in contact with skin H330 Acute Tox. 2 Fatal if inhaled H370 STOT SE 1 H301 Acute Tox. 3 Toxic if swallowed H311 Acute Tox. 3 Toxic in contact with skin H331 Acute Tox. 3 Toxic if inhaled H370 STOT SE 1 H302 Acute Tox. 4 Harmful if swallowed H312 Acute Tox. 4 Harmful in contact with skin H332 Acute Tox. 4 Harmful if inhaled H304 Asp. Tox. 1 H371 STOT SE 2 (May cause damage to organs (or state all organsaffected if known) (state route of exposure if it is conclusively proventhat no other routes of exposure cause the hazard) Other toxicological properties H336 STOT SE 3 May cause drowsiness or dizziness
|
It is concluded that the substance sodium cumenesulphonate does not meet the criteria to be classified for human health hazards for acute oral, inhalation and dermal effects.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.